Gaochao Lv1, Ke Li1, Ling Qiu2, Ying Peng1, Xueyu Zhao1, Xi Li1, Qingzhu Liu1, Shanshan Wang1, Jianguo Lin3. 1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China. 2. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China. qiuling@jsinm.org. 3. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China. linjianguo@jsinm.org.
Abstract
PURPOSE: Improving the targeting efficiency of imaging agents or anticancer drugs has become essential in the current primary mission to enhance the diagnostic or therapeutic effects. To improve the tumor diagnosis and therapy effect, a promising drug-delivery and targeting strategy was established based on the bioorthogonal chemistry. METHOD: The delivery system was composed of the pre-targeting carrier Biotin-MSNs-DBCO nanoparticles and the azido cargoes. The fluorescence probe 1-(3-azidopropyl) fluorescein (FITC-N3) and ruthenium N-heterocyclic carbene complex N3-S-S-NHC-Ru were synthesized and served as the tumor imaging and therapy probes, respectively. The cell imaging and viability was investigated by the Biotin-MSNs-DBCO pre-targeted for 4 h in colonic carcinoma (HeLa) cells. RESULTS: For the tumor cell imaging, Biotin-MSNs-DBCO could react with FITC-N3 rapidly and completely in 20 min with 93% yields. The fluorescence intensity of tumor cells was obviously increased by the Biotin-MSNs-DBCO pre-targeted. The cytotoxicity of the ruthenium complex N3-S-S-NHC-Ru was significantly improved appropriately three times with the IC50 (half inhibitory concentration) value of 6.68 ± 1.29 μM and enhancement of the mitochondrial dysfunction. CONCLUSIONS: The pre-targeting nanoparticle Biotin-MSNs-DBCO could selectively capture the azido compounds in tumor cells, which provided a site-specific target for the cargoes and then resulted in an enhancement of diagnostic or therapeutic effects.
PURPOSE: Improving the targeting efficiency of imaging agents or anticancer drugs has become essential in the current primary mission to enhance the diagnostic or therapeutic effects. To improve the tumor diagnosis and therapy effect, a promising drug-delivery and targeting strategy was established based on the bioorthogonal chemistry. METHOD: The delivery system was composed of the pre-targeting carrier Biotin-MSNs-DBCO nanoparticles and the azido cargoes. The fluorescence probe 1-(3-azidopropyl) fluorescein (FITC-N3) and ruthenium N-heterocyclic carbene complex N3-S-S-NHC-Ru were synthesized and served as the tumor imaging and therapy probes, respectively. The cell imaging and viability was investigated by the Biotin-MSNs-DBCO pre-targeted for 4 h in colonic carcinoma (HeLa) cells. RESULTS: For the tumor cell imaging, Biotin-MSNs-DBCO could react with FITC-N3 rapidly and completely in 20 min with 93% yields. The fluorescence intensity of tumor cells was obviously increased by the Biotin-MSNs-DBCO pre-targeted. The cytotoxicity of the ruthenium complex N3-S-S-NHC-Ru was significantly improved appropriately three times with the IC50 (half inhibitory concentration) value of 6.68 ± 1.29 μM and enhancement of the mitochondrial dysfunction. CONCLUSIONS: The pre-targeting nanoparticle Biotin-MSNs-DBCO could selectively capture the azido compounds in tumor cells, which provided a site-specific target for the cargoes and then resulted in an enhancement of diagnostic or therapeutic effects.
Authors: Zilu Li; Daniel L Clemens; Bai-Yu Lee; Barbara Jane Dillon; Marcus A Horwitz; Jeffrey I Zink Journal: ACS Nano Date: 2015-10-09 Impact factor: 15.881
Authors: Shuang Hou; Jin-Sil Choi; Mitch Andre Garcia; Yan Xing; Kuan-Ju Chen; Yi-Ming Chen; Ziyue K Jiang; Tracy Ro; Lily Wu; David B Stout; James S Tomlinson; Hao Wang; Kai Chen; Hsian-Rong Tseng; Wei-Yu Lin Journal: ACS Nano Date: 2016-01-12 Impact factor: 15.881
Authors: David M Goldenberg; Chien-Hsing Chang; Edmund A Rossi; William J; Robert M Sharkey Journal: Theranostics Date: 2012-05-17 Impact factor: 11.556
Authors: Benoît Bertrand; Julio Fernandez-Cestau; Jesus Angulo; Marco M D Cominetti; Zoë A E Waller; Mark Searcey; Maria A O'Connell; Manfred Bochmann Journal: Inorg Chem Date: 2017-04-25 Impact factor: 5.165
Authors: Rafael R Castillo; Daniel Lozano; Blanca González; Miguel Manzano; Isabel Izquierdo-Barba; María Vallet-Regí Journal: Expert Opin Drug Deliv Date: 2019-04-22 Impact factor: 6.648
Authors: Miguel Gisbert-Garzarán; Daniel Lozano; Kotaro Matsumoto; Aoi Komatsu; Miguel Manzano; Fuyuhiko Tamanoi; María Vallet-Regí Journal: ACS Appl Mater Interfaces Date: 2021-02-17 Impact factor: 9.229